Keros Therapeutics (KROS) Competitors $13.64 -0.15 (-1.09%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. OGN, XENE, ARWR, AMRX, MIRM, VCEL, NAMS, KNSA, DNLI, and CGONShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Organon & Co. (OGN), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Kiniksa Pharmaceuticals (KNSA), Denali Therapeutics (DNLI), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Organon & Co. Xenon Pharmaceuticals Arrowhead Pharmaceuticals Amneal Pharmaceuticals Mirum Pharmaceuticals Vericel NewAmsterdam Pharma Kiniksa Pharmaceuticals Denali Therapeutics CG Oncology Organon & Co. (NYSE:OGN) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Does the MarketBeat Community believe in OGN or KROS? Keros Therapeutics received 47 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 69.07% of users gave Keros Therapeutics an outperform vote while only 34.48% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformOrganon & Co.Outperform Votes2034.48% Underperform Votes3865.52% Keros TherapeuticsOutperform Votes6769.07% Underperform Votes3030.93% Does the media prefer OGN or KROS? In the previous week, Organon & Co. had 29 more articles in the media than Keros Therapeutics. MarketBeat recorded 44 mentions for Organon & Co. and 15 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.40 beat Organon & Co.'s score of 0.04 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 2 Very Positive mention(s) 2 Positive mention(s) 37 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in OGN or KROS? 77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 2.0% of Organon & Co. shares are owned by insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, OGN or KROS? Organon & Co. has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Is OGN or KROS more profitable? Organon & Co. has a net margin of 13.49% compared to Keros Therapeutics' net margin of -27,890.94%. Organon & Co.'s return on equity of 431.62% beat Keros Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organon & Co.13.49% 431.62% 8.03% Keros Therapeutics -27,890.94%-41.74%-38.42% Which has higher earnings & valuation, OGN or KROS? Organon & Co. has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganon & Co.$6.29B0.42$864M$2.883.50Keros Therapeutics$214.71M2.58-$152.99M-$0.18-75.78 Do analysts rate OGN or KROS? Organon & Co. presently has a consensus price target of $18.00, suggesting a potential upside of 78.75%. Keros Therapeutics has a consensus price target of $30.56, suggesting a potential upside of 124.01%. Given Keros Therapeutics' higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryOrganon & Co. beats Keros Therapeutics on 10 of the 18 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$553.99M$6.94B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-2.628.7927.2619.97Price / Sales2.58263.06412.06157.64Price / CashN/A65.8538.2534.64Price / Book1.236.597.064.69Net Income-$152.99M$144.20M$3.24B$248.14M7 Day Performance-9.73%3.81%2.56%2.39%1 Month Performance-0.73%11.10%8.75%6.06%1 Year Performance-72.15%3.95%31.30%13.57% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.6506 of 5 stars$13.64-1.1%$30.56+124.0%-71.2%$553.99M$214.71M-2.62100Analyst DowngradeOGNOrganon & Co.4.7957 of 5 stars$9.25-3.0%$18.00+94.7%-50.1%$2.41B$6.29B2.7810,000Trending NewsXENEXenon Pharmaceuticals3.6794 of 5 stars$31.10+2.1%$54.82+76.3%-15.0%$2.38B$7.50M-10.98210Positive NewsOptions VolumeAnalyst RevisionARWRArrowhead Pharmaceuticals3.6049 of 5 stars$16.70-0.2%$43.71+161.8%-32.1%$2.31B$545.21M-3.23400Analyst RevisionAMRXAmneal Pharmaceuticals3.728 of 5 stars$7.20-0.2%$11.50+59.8%+10.7%$2.26B$2.83B-10.587,600MIRMMirum Pharmaceuticals3.2193 of 5 stars$44.54-0.2%$60.73+36.3%+85.0%$2.21B$379.25M-22.06140Analyst RevisionVCELVericel2.6548 of 5 stars$43.84+1.5%$61.14+39.5%+2.0%$2.20B$238.54M728.29300Positive NewsNAMSNewAmsterdam Pharma2.9774 of 5 stars$19.27-0.6%$42.86+122.5%+3.2%$2.16B$47.14M-10.234Trending NewsAnalyst ForecastAnalyst RevisionKNSAKiniksa Pharmaceuticals3.2514 of 5 stars$29.06+0.6%$38.80+33.5%+61.1%$2.12B$481.17M-207.52220Trending NewsInsider TradeDNLIDenali Therapeutics4.3475 of 5 stars$14.26-1.1%$33.71+136.5%-29.7%$2.06B$330.53M-5.15430Positive NewsAnalyst RevisionCGONCG Oncology2.5014 of 5 stars$27.03+1.7%$58.22+115.4%-25.6%$2.06B$662K-17.8861Positive NewsAnalyst Revision Related Companies and Tools Related Companies Organon & Co. Alternatives Xenon Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Amneal Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives Vericel Alternatives NewAmsterdam Pharma Alternatives Kiniksa Pharmaceuticals Alternatives Denali Therapeutics Alternatives CG Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KROS Stock Free KROS Stock Alerts